[{"orgOrder":0,"company":"NewLimit","sponsor":"Kleiner Perkins","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"NewLimit","amount2":0.13,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"NewLimit \/ Kleiner Perkins","highestDevelopmentStatusID":"4","companyTruncated":"NewLimit \/ Kleiner Perkins"}]

Find Clinical Drug Pipeline Developments & Deals by NewLimit

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          China Battery Fair
                          Not Confirmed
                          China Battery Fair
                          Not Confirmed

                          Details : The proceeds will be used to push a liver-rejuvenating mRNA medicine into clinic. The preclinical asset uses lipid nanoparticles to deliver mRNA to liver cells that codes for transcription factors.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          May 06, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Preclinical

                          Sponsor : Kleiner Perkins

                          Deal Size : $130.0 million

                          Deal Type : Series B Financing

                          blank